In vitro studies have shown that DHT suppresses the development and multiplication of BRAF mutant melanoma cells, prevents the compensatory stimulation of the STAT3 signal in these cells, and improves the therapeutic efficacy of MAPK inhibitors. The gene discussed is BRAF; the disease is melanoma.